SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Reports Promising Data For ASC30 Obesity Treatment In U.S. Trials
Ascletis Pharma (SEHK:1672) recently announced noteworthy advancements related to its investigational drug ASC30, showcasing a promising 75-day half-life in a clinical study, which propelled excitement around potential once-quarterly administration for obesity management. As a result, the company's share price increased by nearly 48% over the last quarter. This rise occurred against a backdrop of broader market gains, with indexes like the Nasdaq and S&P 500 reaching all-time highs,...
